Skip to main content

Table 1 Participant characteristics

From: Gadolinium free cardiovascular magnetic resonance with 2-point Cine balanced steady state free precession

Variable

Healthy Control (Group I)

CVD without Enhancement (Group II)

CVD with Enhancement (Groups III, IV)

p-value

(n = 10)

(n = 24)

(n = 23)

Demographics

    

 Age (yrs)

51.74 ± 4.7

47.7 ± 16.5

51.39 ± 15.4

.406

 BMI (kg/m2)

23.32 ± 1.5

29.3 ± 6.7

27.4 ± 3.6

.007

 Female

4 (50.0)

8 (33.3)

4 (17.4)

.315

 White

9 (90.0)

20 (83.3)

18 (78.3)

.815

 African American

0

3 (12.5)

3 (13.0)

1.00

 Hispanic or Other Race

1 (10.0)

1 (4.2)

2 (8.7)

.051

CMR Indication

    

 Cardiomyopathy

 

7 (29.2)

10 (43.5)

.371

 Hypertrophic Cardiomyopathy

 

2 (8.3)

1 (4.3)

1.000

 Pericarditis, Myocarditis

 

2 (8.3)

2 (8.7)

1.000

 Sarcoidosis

 

2 (8.3)

2 (8.7)

1.000

 Syncope

 

4 (16.7)

0

.109

 Viability

 

3 (12.5)

5 (21.1)

.461

 Other

 

4 (16.7)

3 (17.4)

1.000

Diagnosis

    

 Ischemic Cardiomyopathy

 

4 (16.7)

10 (43.5)

.060

 Non-Ischemic Cardiomyopathy

 

10 (41.7)

7 (30.4)

.547

 Hypertrophic Cardiomyopathy

 

0

2 (8.7)

.234

 No Evidence of Cardiomyopathy

 

8 (33.3)

0

.416

 Other

 

2 (8.3)

4 (17.4)

.416

Ejection Fraction (%)

 

50.13 ± 14.4

42.57 ± 14.6

.081

End Diastolic Volume (mL)

 

190.6 ± 76.0

217.65 ± 81.1

.244

  1. CVD without Enhancement: Patients referred for CMR not demonstrating LGE enhancement in imaged slice
  2. CVD with Enhancement: Patients referred for CMR demonstrating LGE enhancement in imaged slice
  3. BMI: Body Mass Index (kg/m2)